Loading
A blood test for leftover cancer after surgery that needs no tumour sample, so results come faster than tumour-informed tests.
Guardant Reveal launched in 2021 as the first tissue-free MRD test, initially for stage II-III colorectal cancer, with Medicare coverage for colorectal cancer surveillance and later breast and lung indications. Tumour-naive design gives a result within about a week of surgery and suits patients whose tissue is unavailable, at the cost of somewhat lower sensitivity than bespoke tumour-informed panels such as Signatera. Published colorectal data show ctDNA positivity after surgery carries a high risk of recurrence, and serial negative results are strongly reassuring. It is a laboratory-developed test under CLIA.
Blood-only assay combining somatic variant detection with cancer-specific methylation signals, so no tumour tissue is needed to design the test.
1.Guardant Reveal slips into a pocket on its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Guardant Reveal" OR ABSTRACT:"Guardant Reveal") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Guardant Reveal, not a curated reading list.
Shares ctDNA MRD positivity (molecular residual disease after curative treatment), Signatera, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA) and the tag test.
Shares Diagnostics roadmap: stains → gene panels → blood tests that decide treatment, ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, Circulating tumour DNA (ctDNA), Liquid biopsy (ctDNA) and the tag test.
Shares Guardant Health, Diagnostics roadmap: stains → gene panels → blood tests that decide treatment, ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, Circulating tumour DNA (ctDNA) and the tag test.
Shares Circulating tumour DNA (ctDNA), Liquid biopsy (ctDNA), Non-small-cell lung cancer and the tag test.
Shares Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, Colorectal cancer, Non-small-cell lung cancer and the tag test.
Shares ctDNA MRD positivity (molecular residual disease after curative treatment), Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing and the tag test.
Shares Diagnostics roadmap: stains → gene panels → blood tests that decide treatment, Triple-negative breast cancer (TNBC), Colorectal cancer and the tag test.
Shares Diagnostics roadmap: stains → gene panels → blood tests that decide treatment, Triple-negative breast cancer (TNBC), Colorectal cancer and the tag test.